Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TransMedics Group Inc (TMDX) vs WD 40 Company (WDFC) Price & Performance

TransMedics Group IncTrade
WD 40 CompanyTrade

Price performance (Past 24H)

Key statistics

TransMedics Group Inc vs WD 40 Company — how do they compare? TransMedics Group Inc trades at $87.62 (market cap $3.10B), while WD 40 Company trades at $232.96 (market cap $3.13B). The key difference: TransMedics Group Inc and WD 40 Company are close in size by market cap, and WD 40 Company pays a 1.75% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

TMDXWDFC
Market Cap
$3.10B$3.13B
Sector
TechnologyTechnology
52-Week High
$150.42$264.91
52-Week Low
$61.99$187.52
Enterprise Value
$3.49B$3.18B
Dividend Yield
1.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TransMedics Group Inc

TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.

Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.

WD 40 Company

WD-40 Company (WDFC) trades at $232.9, down 0.69% today, with strong technical momentum showing bullish moving averages and key support at $230. The company reported impressive Q2 2026 earnings of $2.33 per share, beating estimates by 49%, while revenue growth continues with 2026 projections at $675 million. Recent news highlights institutional buying and positive analyst coverage, though valuation metrics remain elevated with a P/E of 35.39.

WDFC demonstrates solid fundamentals with consistent profitability (13.22% net margin) and strong brand positioning, but faces margin pressure from rising input costs. Analyst sentiment is mixed with 71% hold ratings, suggesting cautious optimism. Key risks include valuation concerns and cost inflation, while the company's dividend policy and global brand recognition provide stability for long-term investors.

Returns comparison

Trailing returns across standard periods

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX

About WD 40 Company

WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.

Read more on WDFC